shortagewatch

Home / Companies / Eli Lilly

Company family · HQ US

Eli Lilly: medicine shortages

LLY · NYSE

As of 2 Nov 2026, 37 Eli Lilly products have a reported shortage across 5 countries, covering 12 medicines.

Products short37rank #57 of 464
Medicines12active ingredients
Countries5/16
New in 90 days11+3 vs market pace
Typical duration12 monthsmedian so far
Manufacturing0%demand-driven 27%

Where

United States11Canada10Spain2Belgium1Japan13

Which therapeutic classes

Digestive tract and metabolism15Nervous system11Cancer and immune system4Systemic hormones2

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Eli LillyEli Lilly: Increased demand 6 (16%)16%Eli Lilly: Other 16 (43%)43%Eli Lilly: Not stated 15 (41%)41%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

025710Dec: 0Jan ’25: 1Feb: 0FebMar: 2Apr: 1May: 1MayJun: 1Jul: 0Aug: 2AugSep: 0Oct: 2Nov: 6NovDec: 2Jan ’26: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 2Jul: 2Aug: 0AugSep: 4Oct: 7Nov: 0Nov

Long-run trend in Canada

Canada dashboard
051015202020: 1120202021: 2220212022: 7720222023: 121220232024: 141420242025: 9920252026: 222026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Eli Lilly37

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Eli Lilly: 37 / 12Eli Lilly

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Lasmiditan63 Nov 2025Not stated1/16
Tirzepatide622 Jan 2025Other1/16
Atomoxetine512 Nov 2024Other11/16
Insulin Glargine31 Sep 2026Increased demand6/16
Insulin Lispro21 Sep 2026Not stated3/16
Mirikizumab222 Dec 2025Not stated1/16
Selpercatinib222 Jul 2026Other1/16
Somatropin222 Jul 2026Not stated4/16
Dulaglutide19 Feb 2024Other1/16
Insulin (Human)1not givenNot stated1/16
Insulin (Human)1not givenNot stated1/16
Insulin Lispro115 Oct 2026Increased demand1/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.